Cd55-deficient Protein-losing Enteropathy
📧 Sign up to get email alerts when something new happens for Cd55-deficient Protein-losing Enteropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS approval · 2025-11-10Clinical Trial Update: Compassionate Use of Pozelimab
Pozelimab has been approved for marketing for CD55-deficient Protein-losing Enteropathy under compassionate-use provisions.
-
CLINICAL_TRIALS approval · 2025-11-10Clinical Trial Update: Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy
Pozelimab has been approved for marketing for CD55-Deficient Protein-Losing Enteropathy.
-
CLINICAL_TRIALS trial_result · 2023-10-30Clinical Trial Update: Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) [Phase 2, Phase 3]
Open-label Phase 2/3 trial assessing the efficacy and safety of pozelimab in CD55-deficient protein-losing enteropathy (CHAPLE disease) has …